Background: Cross-sectional studies in childhood have suggested associations between body composition and bone mass. However, there is scant evidence relating to longitudinal change in childhood lean or fat mass in relation to development of bone size, mineralization and density. We therefore investigated, in a population-based cohort, relationships between change in body composition between birth and 6-7 years (assessed by DXA), and childhood bone indices at 6-7 years, assessed by DXA and pQCT. Methods: Participants were recruited from the Southampton Women's Survey (SWS), a prospective mother-offspring cohort study. Body composition [(total fat mass (FM) and total lean mass (LM)] of the offspring was assessed at birth, 4 years and 6-7 years by DXA (Hologic Discovery). At 6-7 years, total cross sectional area (CSA) and trabecular volumetric BMD (vBMD) were assessed at the 4% (metaphysis) site of the right tibia, using peripheral quantitative computed tomography (pQCT, Stratec XCT-2000). Total CSA, cortical CSA, cortical vBMD were measured at the 38% site (diaphysis). FM and LM were adjusted for age and sex and standardized to create within-cohort z-scores. Change in LM or FM was represented by change in z-score between birth and 4 years and between 4 and 6-7 years. Linear regression was used to explore the relationships between change in LM or FM and standardized pQCT outcomes (adjusted for age and sex), with the regression coefficient representing SD change in outcome per unit SD change in predictor. Results: pQCT scans and change in body composition z-scores were available for 122 children from birth to 4years and 181 children from 4 to 7 years. Change in LM z-score (ÁLM) from 0-4 years was positively associated with CSA at both 4% and 38% sites: 4% total CSA (b ¼ 0.26 SD/SD, P ¼ 0.009), 38% total CSA (b ¼ 0.29 SD/SD, P ¼ 0.001) and 38% cortical CSA (b ¼ 0.24 SD/SD, P ¼ 0.008). Similarly, ÁLM from 4-7 years was positively associated with 4% total CSA (b ¼ 0.27 SD/SD, P ¼ 0.08) and 4% trabecular vBMD (b ¼ 0.32 SD/SD, P ¼ 0.04). Although change in fat mass z-score from 0 to 4 years was also associated with 4% total CSA (b ¼ 0.16 SD/SD, P ¼ 0.04), there were no associations between ÁFM from 4 to 7 years and bone geometry or mineralization. Conclusion: In this prospective observational study, gain lean mass during childhood was positively associated with bone size and trabecular vBMD, assessed by pQCT at 6-7 years. In contrast, relationships between bone and change in fat mass were weaker, suggesting that muscle growth, rather than accrual of fat mass, may be a more important determinant of childhood bone development. RJM and ZAC are joint first authors. Disclosure statement: The authors have declared no conflicts of interest. 
O51. GROWTH IN CHILDREN AND ADOLESCENTS WITH JIA AFTER 2 YEARS OF TREATMENT WITH ETANERCEPT: RESULTS FROM THE BRITISH SOCIETY FOR PAEDIATRIC AND ADOLESCENT RHEUMATOLOGY (BSPAR) ETANERCEPT COHORT STUDY
analysis was restricted to patients in the ETN cohort with complete height data at baseline, 1 and 2 years. Patient height at each follow-up was age and sex matched with The WHO Child Growth Standards to calculate a z-score. The change in z-score from baseline to 2 years was calculated. Multiple imputation was used to account for missing data. Multivariate linear regression was used to identify factors associated with change in height z-score from baseline. Growth over 2 years was also compared in those who had and had not achieved Minimal Disease Activity (MDA; defined as polyarticular JIA ¼ PGA 3.4 cm, PGE 2.1 cm, 1 swollen joint; oligoarticular JIA ¼ PGA 2.5 cm, no swollen joints) at 3 months. Patient height velocity over 2 years was visually compared with UK median height velocity standards. Results: 191 ETN treated patients were included; median baseline age 11.0 (7.3-12.9), 65% female, and median disease duration at start of treatment 3.5 years (1.7-7.1) ( Table 1) . At baseline mean height z-score was 0.74 (1.4) standard deviations below the reference mean. After 2 years of ETN treatment the mean height z-score increased by 0.29 (0.5) to a mean of À0.45 (1.4) (P < 0.001). There was a trend towards better improvement in growth over 2 years in children who achieved MDA at 3 months (42%) although this did not reach statistical significance (P ¼ 0.281). In multivariable analysis, factors associated with an improvement in height z-score included lower baseline z-score [-0.110 per unit z-score (95% CI À0.162, À0.059) P < 0.001] and no steroid use at baseline À0.037 
The mean (S.D.) height velocity was calculated as 5.8 cm (2.4) per year. The height velocity of the majority of patients was greater than the median height velocity standards. Conclusion: ETN therapy was associated with an improvement in height z-score over the first 2 years of therapy. Children who were not receiving concurrent steroids had a greater improvement, which may be a marker for less severe disease.
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O52. EFFICACY AND SAFETY OF ADALIMUMAB IN PAEDIATRIC PATIENTS WITH ENTHESITIS RELATED ARTHRITIS
Background: Enthesitis RA (ERA) is a subcategory of JIA, which primarily affects peripheral joints and entheses but can involve the O51 
